Clinical Trial Update: AZD2115 Single Ascending Dose Study [Phase 1]

View source ↗

Summary

A Phase 1 single ascending dose trial of AZD2115 in chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD2115 (AZD2115)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways | Phase 1 | Status: COMPLETED